Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Net Cash Flow: 2013-2025

Historic Net Cash Flow for Coherus Oncology (CHRS) over the last 12 years, with Sep 2025 value amounting to -$113.6 million.

  • Coherus Oncology's Net Cash Flow fell 83.94% to -$113.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.6 million, marking a year-over-year decrease of 67.29%. This contributed to the annual value of $22.9 million for FY2024, which is 41.80% down from last year.
  • As of Q3 2025, Coherus Oncology's Net Cash Flow stood at -$113.6 million, which was down 184.45% from $134.5 million recorded in Q2 2025.
  • Coherus Oncology's Net Cash Flow's 5-year high stood at $156.9 million during Q1 2024, with a 5-year trough of -$281.7 million in Q1 2021.
  • Over the past 3 years, Coherus Oncology's median Net Cash Flow value was $7.4 million (recorded in 2023), while the average stood at $3.6 million.
  • In the last 5 years, Coherus Oncology's Net Cash Flow tumbled by 1,884.52% in 2021 and then spiked by 430.96% in 2024.
  • Coherus Oncology's Net Cash Flow (Quarterly) stood at $56.7 million in 2021, then tumbled by 494.07% to -$223.3 million in 2022, then surged by 110.14% to $22.6 million in 2023, then grew by 25.03% to $28.3 million in 2024, then slumped by 83.94% to -$113.6 million in 2025.
  • Its Net Cash Flow stands at -$113.6 million for Q3 2025, versus $134.5 million for Q2 2025 and -$43.6 million for Q1 2025.